Where now for obesity research?
George A. Bray · Clinical Investigation · 2011
Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.
Clinical Investigation · OMICS Publishing Group · article · 2011
Abstract
As three new applications for pharmacotherapy were submitted to the US FDA for review and approval, 2010 began with hope that the findings from obesity research would translate into new therapies for obese patients [1–3]. During the year, there were actually five Advisory Panels to evaluate proposed drug or drug combinations for the treatment of obesity and review of one older drug where an outcome trial had suggested an increased risk [4] along with a panel to review an expanded indication for surgical treatment with the lap-band.
The results of three panels were negative, with the External Advisory Committees voting against approval of one new drug and one combination treatment using older drugs and no longer favoring marketing of an existing drug. A ray of hope appeared when the final two panels voted to approve a second combination of two older drugs for treatment of obesity and the expanded use of the lap-band at a lower BMI in higher risk obese individuals. Thus, in spite of years of research, only a single drug has been approved by the FDA for long-term use [5]. By contrast, there are many drugs acting through one of several different mechanisms to treat hypertension, atherosclerosis and diabetes.
Why have scientists doing obesity research not been as successful as scientists in these other diseases areas in identifying successful drugs? Drugs to treat obesity can work on structures in the brain, for example, amphetamine, fenfluramine or serotonin [6]. Alternatively, they can work outside the brain by blocking intestinal digestion or as hormonal agents acting on gastrointestinal receptors that can inhibit feeding. One difficulty is that drugs that reduce food intake by acting on brain receptors may also act on other receptors to produce unwanted side effects, such as alterations in mood or other behaviors.
These undesirable, and often unintended, side effects from drugs sounded the death knell for pheylpropanolamine [7], an a-1 adrenergic antagonist that reduces food intake and produces modest weight loss, but is also a vasoconstrictor that can raise blood pressure. In a case-controlled study of strokes, younger women using phenylpropanolmine appeared to be at increased risk for stroke and phenylpropanolamine was subsequently taken off the market by the FDA [7]. Addiction is another problem associated with some centrally acting sympathomimetic drugs. Shortly after amphetamine was shown to reduce body weight, it was also shown to produce addiction.
This probably reflects the fact that it hits two targets, one of which, the norepinephrine receptor, is beneficial and reduces food intake and the other, the dopamine receptor, is harmful and can produce addiction. Drugs reducing food intake by acting on serotonin receptors have also experienced problems. Fenfluramine has a b-phenethylamine structure like amphetamine, but, in contrast to amphetamine, acts almost exclusively on serotonin receptors. Fenfluramine was approved by the FDA in 1975 to treat obesity.
In 1997, patients treated with fenfluramine and phentermine were reported to “The challenges are to find those mechanisms that will produce clinically significant weight loss, provide durable responses and be free of significant side effects.”
Open the resolved locator · 10.4155/cli.11.8
Metadata licence: OpenAlex metadata (CC0)